Concepedia

<i>PIK3CA</i> mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation

Grace R. Anderson, Suzanne E. Wardell, Lorin Crawford, Jim C. Leeds, Daniel P. Nussbaum, Pallavi S. Shankar, Ryan S. Soderquist, Elizabeth M. Stein, Jennifer P. Tingley, Peter Winter,

Science Translational Medicine · 2016 · 58 citations · 37 references

DOIFull text

Open access

Concepts

Abstract

Inhibitors of BCL-X L , combined with inhibition of the mTOR/4E-BP axis, drive regressions of PIK3CA mutant breast tumors.

References

37

Comprehensive molecular portraits of human breast tumours

Nature · 2012 · 12.4K citations · Full text

, , +14

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

Ophir Shalem, Neville E. Sanjana, Ella Hartenian et al. · Science · 2013 · 5.5K citations · Full text

, , +17

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations

, , +14

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text

, , +16

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text

, , +14